通过单细胞分析,HPv驱动的瘤免疫微环境的重新连接,为HNSCC的预后和治疗提供了信息
Ying Li1, Qianzi Kou1, Chongyang Zheng1
1Department of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, No.253 Mid Gongye Ave, Haizhu District, Guangzhou City 510282 Guangdong Province, China.
Oral oncology
|November 28, 2025
概括
人类乳头瘤病毒 (HPV) 感染显著改变了头部和部状细胞癌 (HNSCC) 瘤免疫微环境 (TIME). 一个新的七基因签名预测了生存率,并通过反映时间特征来指导个性化治疗.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
背景情况:
- 人类乳头瘤病毒 (HPV) 状态是头部和部状细胞癌 (HNSCC) 的关键预后因素.
- 由于HPV驱动的HNSCC的确切免疫机制和生物标志物尚不清楚,这阻碍了个性化治疗策略.
- 了解HPV对瘤免疫微环境 (TIME) 的影响对于治疗进展至关重要.
研究的目的:
- 综合分析HPV感染如何重编程HNSCC中的TIME.
- 开发一种新的预后模型,用于分层HNSCC患者的结果,并预测治疗反应.
- 确定强大的生物标志物,以指导HNSCC的个性化治疗.
主要方法:
- 整合来自TCGA和GEO数据库的多主题数据.
- 使用批量转录组学和单细胞RNA测序 (scRNA-seq) 的HPV阳性 (HPV+) 和HPV阴性 (HPV-) HNSCC中免疫景观的比较.
- 基于使用LASSO-COX回归的HPV相关基因构建和验证预后风险特征.
主要成果:
- 单细胞剖析显示,HPV+瘤具有免疫活性时间,细胞毒性T细胞,辅助T细胞和B细胞增加,而HPV-瘤显示出免疫抑制性,丰富 stromal 的利基.
- 一个经过验证的七基因预后模型 (IER3,FHL2,MBOAT2,DSC3,IRAK3,RGMA,BARD1) 通过生存率 (P < 0.0001) 强有力的分层患者,并作为一个独立的预后因素.
- 低风险组 (HPV+表型) 呈现出激活的免疫微环境,更高的免疫检查点表达,并预测了对化疗和免疫疗法的反应性;高风险组 (HPV-表型) 显示出无菌的免疫格局和对向药物的敏感性.
结论:
- 单细胞剖析有效阐明了HPV驱动的免疫重塑在HNSCC.
- 衍生出的预后签名准确地反映了 TIME,作为预测 HNSCC 患者存活率的可靠生物标志物.
- 这种签名有可能弥合HPV状态和临床决策之间的差距,为精确治疗提供信息.
更多相关视频
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
10.2K
07:43Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples
Published on: July 29, 2017
10.2K
相关概念视频
02:07Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K